HC Wainwright Predicts Rezolute’s Q1 Earnings (NASDAQ:RZLT)

Rezolute, Inc. (NASDAQ:RZLT) – Investment analysts at HC Wainwright lowered their Q1 2027 EPS estimates for shares of Rezolute in a research note issued on Friday, September 25th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.16) per share for the quarter, down from their prior forecast of ($0.12). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Rezolute’s Q2 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.57) EPS, Q1 2028 earnings at ($0.13) EPS, Q2 2028 earnings at ($0.12) EPS, Q3 2028 earnings at ($0.10) EPS, Q4 2028 earnings at $0.01 EPS, FY2028 earnings at ($0.34) EPS, FY2029 earnings at ($0.14) EPS, FY2030 earnings at $1.42 EPS and FY2031 earnings at $2.94 EPS.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05).

A number of other analysts have also recently issued reports on the company. Citizens Jmp upgraded Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 price objective on the stock in a research report on Wednesday, June 3rd. Wedbush lifted their price target on shares of Rezolute from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Maxim Group boosted their price target on shares of Rezolute from $10.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Guggenheim raised their price objective on shares of Rezolute from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, June 15th. Finally, Craig Hallum upgraded shares of Rezolute from a “hold” rating to a “buy” rating and lifted their target price for the company from $4.00 to $7.00 in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.62.

Rezolute Stock Down 2.2%

Rezolute stock opened at $4.09 on Tuesday. The business has a 50 day moving average price of $4.55 and a two-hundred day moving average price of $4.04. The stock has a market cap of $395.58 million, a price-to-earnings ratio of -5.38 and a beta of 0.60. Rezolute has a 12 month low of $1.07 and a 12 month high of $11.46.

Institutional Investors Weigh In On Rezolute

Large investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. acquired a new position in Rezolute in the fourth quarter valued at about $35,000. Auxano Advisors LLC acquired a new stake in shares of Rezolute during the second quarter worth approximately $52,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Rezolute during the second quarter worth approximately $75,000. WINTON GROUP Ltd bought a new position in shares of Rezolute in the second quarter valued at approximately $88,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Rezolute in the 1st quarter worth approximately $90,000. Institutional investors own 82.97% of the company’s stock.

More Rezolute News

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: Craig Hallum upgraded Rezolute from “Hold” to “Buy” and raised its price target from $4 to $7, implying substantial upside from the recently cited $4.09 level. The upgrade is a direct positive catalyst for RZLT.
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $10 price target. Its forecasts anticipate Rezolute reaching positive earnings in 2028 and significant profitability by 2030 and 2031, including projected EPS of $1.42 in fiscal 2030 and $2.94 in fiscal 2031. These estimates reflect the potential for substantial long-term operating improvement.
• Neutral Sentiment: The analyst targets remain well above the recent share price, but they differ materially: Craig Hallum’s new target is $7, while HC Wainwright continues to target $10. This indicates broad upside expectations, but also highlights uncertainty around Rezolute’s valuation and execution.
• Negative Sentiment: HC Wainwright reduced several near-term earnings forecasts. Estimates were lowered for Q1 2027 EPS to $(0.16) from $(0.12), Q2 2027 EPS to $(0.14) from $(0.10), Q4 2027 EPS to $(0.13) from $(0.09), and fiscal 2027 EPS to $(0.57) from $(0.45). Fiscal 2028 EPS was also trimmed slightly to $(0.34) from $(0.33). The revisions suggest larger expected losses before the company reaches projected profitability. Rezolute Stock Earnings Estimates Decreased by HC Wainwright

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.